Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

New Molecules of Importance in the Prevention and Treatment of Acne: A Systematic Patent Review (2016-2020)

Author(s): Daniela Estefanía Calderón-Pardo, Mairim Russo Serafini, Izabel Almeida Alves and Diana Marcela Aragón*

Volume 31, Issue 21, 2024

Published on: 22 September, 2023

Page: [3182 - 3197] Pages: 16

DOI: 10.2174/0929867331666230817155906

Price: $65

Abstract

Background: Acne is a highly prevalent disease that mainly affects the pilosebaceous units associated with sebaceous glands, causing inflammatory skin lesions and affecting the self-esteem, mental health, and quality of life of those who suffer from this disease. Different treatments exist today to prevent, reduce, and improve symptoms; however, over the years, there have been problems with bacterial resistance and slight effectiveness with prolonged use.

Objective: The purpose of this article is based on the review of patents of new products of principal topical administration for the treatment of acne in recent years 2016-2020, to evaluate and analyze novel synthetic molecules and semi-synthetics with potential therapeutic and preventive in the acne treatment.

Methods: A systematic review of patents was conducted through the official database of the European Patent Office - Espacenet, where the search focused on the keywords: "acne and bacteria" in the title or abstract. Only patents granted between the years 2016-2020 were included, with products having molecules with a synthetic and semi-synthetic origin, without considering natural, biological products or those used as diagnostic means.

Results: A total of 19 patents were selected, most with principally antimicrobial and antiinflammatory action, where the reduction in the appearance of resistance by C. acnes is verified, and its action is complemented by inhibiting the different pathophysiological mechanisms that lead to the worsening of the disease.

Conclusion: Novel approaches in the treatment and prevention of acne, mainly topically, are focused on the reduction of bacterial resistance and irritation compared to current treatments. The use of combined formulations provides better results with additional benefits, improving treatment times and patient adherence.

« Previous Next »
[1]
Knutsen-Larson, S.; Dawson, A.L.; Dunnick, C.A.; Dellavalle, R.P. Acne vulgaris: Pathogenesis, treatment, and needs assessment. Dermatol. Clin., 2012, 30(1), 99-106. viii-ix.
[http://dx.doi.org/10.1016/j.det.2011.09.001] [PMID: 22117871]
[2]
Williams, H.C.; Dellavalle, R.P.; Garner, S. Acne vulgaris. Lancet, 2012, 379(9813), 361-372.
[http://dx.doi.org/10.1016/S0140-6736(11)60321-8] [PMID: 21880356]
[3]
Beylot, C.; Auffret, N.; Poli, F.; Claudel, J.P.; Leccia, M.T.; Del Giudice, P.; Dreno, B. Propionibacterium acnes: An update on its role in the pathogenesis of acne. J. Eur. Acad. Dermatol. Venereol., 2014, 28(3), 271-278.
[http://dx.doi.org/10.1111/jdv.12224] [PMID: 23905540]
[4]
Kraft, J.; Freiman, A. Management of acne. CMAJ, 2011, 183(7), E430-5.
[5]
Fox, L.; Csongradi, C.; Aucamp, M.; du Plessis, J.; Gerber, M. Treatment modalities for acne. Molecules, 2016, 21(8), 1063.
[http://dx.doi.org/10.3390/molecules21081063] [PMID: 27529209]
[6]
SC Johnson College of Business, World International Property (WIPO). Global Innovation Index. 13th edition. 2020. Avialable from: https://www.wipo.int/global_innovation_ index/en/2020/
[7]
Zhao, J.; Wang, Y.; Jiang, L.; Mu, Y.Z. The application of skin care product in acne treatment. Dermatol. Ther., 2020, 33(6), e14287.
[http://dx.doi.org/10.1111/dth.14287] [PMID: 32897611]
[8]
International Trade Administration. South Korea – Country Commercial Guide. 2022. Avialable from: https://www. trade.gov/country-commercial-guides/south-korea-cosme-tics
[9]
WIPO IP PORTAL. IPC Publication. 2023. Avialable From: https://ipcpub.wipo.int/
[10]
Kumazawa, R. Patenting in the Pharmaceutical Industry. Intellectual Property Rights; IntechOpen Limited: London, 2017.
[http://dx.doi.org/10.5772/68102]
[11]
Mukherjee, A. Licensing a new product: Fee vs. royalty licensing with unionized labor market. Labour Econ., 2010, 17(4), 735-742.
[http://dx.doi.org/10.1016/j.labeco.2009.09.003]
[12]
Ministry of Food and Drug Safety. Cosmetics regulation. 2023. Avialable From: https://www.mfds.go.kr/eng/wpge/m_24/de011014l001.do
[13]
Weir, C.B.; Le, J.K. Metronidazole; StatPearls: Treasure Island, 2022.
[14]
Lin, A.N.; Reimer, R.J.; Carter, D.M. Sulfur revisited. J. Am. Acad. Dermatol., 1988, 18(3), 553-558.
[http://dx.doi.org/10.1016/S0190-9622(88)70079-1] [PMID: 2450900]
[15]
Trivedi, M.K.; Bosanac, S.S.; Sivamani, R.K.; Larsen, L.N. Emerging therapies for acne vulgaris. Am. J. Clin. Dermatol., 2018, 19(4), 505-516.
[http://dx.doi.org/10.1007/s40257-018-0345-x] [PMID: 29594974]
[16]
Dréno, B.; Pécastaings, S.; Corvec, S.; Veraldi, S.; Khammari, A.; Roques, C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: A brief look at the latest updates. J. Eur. Acad. Dermatol. Venereol., 2018, 32(Suppl. 2), 5-14.
[http://dx.doi.org/10.1111/jdv.15043] [PMID: 29894579]
[17]
Bannatyne, R.M. Metronidazole, its bioactive metabolites and acne. Curr. Med. Res. Opin., 1999, 15(4), 298-299.
[http://dx.doi.org/10.1185/03007999909116500] [PMID: 10640262]
[18]
Song, M.; Seo, S.H.; Ko, H.C.; Oh, C.K.; Kwon, K.S.; Chang, C.L.; Kim, M.B. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea. J. Dermatol., 2011, 38(7), 667-673.
[http://dx.doi.org/10.1111/j.1346-8138.2010.01109.x] [PMID: 21352337]
[19]
Okamoto, K.; Ikeda, F.; Kanayama, S.; Nakajima, A.; Matsumoto, T.; Ishii, R.; Umehara, M.; Gotoh, N.; Hayashi, N.; Iyoda, T.; Matsuzaki, K.; Matsumoto, S.; Kawashima, M. In vitro antimicrobial activity of benzoyl peroxide against Propionibacterium acnes assessed by a novel susceptibility testing method. J. Infect. Chemother., 2016, 22(6), 426-429.
[http://dx.doi.org/10.1016/j.jiac.2015.12.010] [PMID: 26806150]
[20]
Wang, Y.; Kuo, S.; Shu, M.; Yu, J.; Huang, S.; Dai, A.; Two, A.; Gallo, R.L.; Huang, C.M. Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: Implications of probiotics in acne vulgaris. Appl. Microbiol. Biotechnol., 2014, 98(1), 411-424.
[http://dx.doi.org/10.1007/s00253-013-5394-8] [PMID: 24265031]
[21]
Kaur-Boparai, J.; Sharma, P.K. Mini review on antimicrobial peptides, sources, mechanism and recent applications. Protein Pept. Lett., 2020, 27(1), 4-16.
[http://dx.doi.org/10.2174/18755305MTAwENDE80] [PMID: 31438824]
[22]
Malmsten, M. Antimicrobial peptides. Ups. J. Med. Sci., 2014, 119(2), 199-204.
[http://dx.doi.org/10.3109/03009734.2014.899278] [PMID: 24758244]
[23]
Dréno, B. What is new in the pathophysiology of acne, an overview. J. Eur. Acad. Dermatol. Venereol., 2017, 31(Suppl. 5), 8-12.
[http://dx.doi.org/10.1111/jdv.14374] [PMID: 28805938]
[24]
Marta Guarna, M.; Coulson, R.; Rubinchik, E. Anti-inflammatory activity of cationic peptides: Application to the treatment of acne vulgaris. FEMS Microbiol. Lett., 2006, 257(1), 1-6.
[http://dx.doi.org/10.1111/j.1574-6968.2006.00156.x] [PMID: 16553825]
[25]
Das, S.; Reynolds, R.V. Recent advances in acne pathogenesis: Implications for therapy. Am. J. Clin. Dermatol., 2014, 15(6), 479-488.
[http://dx.doi.org/10.1007/s40257-014-0099-z] [PMID: 25388823]
[26]
Jugeau, S.; Tenaud, I.; Knol, A.C.; Jarrousse, V.; Quereux, G.; Khammari, A.; Dreno, B. Induction of toll-like receptors by Propionibacterium acnes. Br. J. Dermatol., 2005, 153(6), 1105-1113.
[http://dx.doi.org/10.1111/j.1365-2133.2005.06933.x] [PMID: 16307644]
[27]
Kim, J.; Ochoa, M.T.; Krutzik, S.R.; Takeuchi, O.; Uematsu, S.; Legaspi, A.J.; Brightbill, H.D.; Holland, D.; Cunliffe, W.J.; Akira, S.; Sieling, P.A.; Godowski, P.J.; Modlin, R.L. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol., 2002, 169(3), 1535-1541.
[http://dx.doi.org/10.4049/jimmunol.169.3.1535] [PMID: 12133981]
[28]
Matsuzawa-Ishimoto, Y.; Hwang, S.; Cadwell, K. Autophagy and Inflammation. Annu. Rev. Immunol., 2018, 36(1), 73-101.
[http://dx.doi.org/10.1146/annurev-immunol-042617-053253] [PMID: 29144836]
[29]
Lee, Y.; Shin, K.; Shin, K.O.; Yoon, S.; Jung, J.; Hwang, E.; Chung, H.J.; Hossini, A.M.; Zouboulis, C.C.; Baek, M.J.; Baek, J.H.; Chi, Y.M.; Lee, S.; Jeong, S. Topical application of autophagy‐activating peptide improved skin barrier function and reduced acne symptoms in acne‐prone skin. J. Cosmet. Dermatol., 2021, 20(3), 1009-1016.
[http://dx.doi.org/10.1111/jocd.13636] [PMID: 32697858]
[30]
Johnson, B.A.; Nunley, J.R. Topical therapy for acne vulgaris. Postgrad. Med., 2000, 107(3), 69-80, 73-76, 79-80.
[http://dx.doi.org/10.3810/pgm.2000.03.945] [PMID: 10728136]
[31]
Food and Drug Administration FDA. Cosmetics & U.S. Law. 2022. Avialable from: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/cosmetics-us-law
[32]
Jeong, S.; Gue, S.D.; Cha, J.D.; Ko, E.S.; Cho, S.M.; Jung, J.H. Composition for the treatment or improvement of Acne dermatitis comprising 5-aminolevulinic acid hydrochloride and its derivatives. KR Patent KR102171200B1, KR20200058699A, 2020.
[33]
Keedon, P.; Chung, H.J.; Heungjae, K.; Kayoung, S.; Juyeon, J.; Beomcheol, K. Beomcheol, A cosmetic and pharmaceutical composition for acne improvement. KR Patent KR20200064762A, 2020.
[34]
Chul, H.K.; Yang, K.T.; Mong, L.C.; Kook, L.K. A cosmetic composition for reducing acne and inhibiting sebum secretion containing chrysophanol mangiferin and shikonofuran A. KR Patent KR101987717B1, 2019.
[35]
Masatoshi, H.; Keita, M. Acne bacteria biofilm destructive composition. JP Patent JP2020050679A, 2020.
[36]
Liu, Y. Acne removing and whitening lotion and preparation method thereof. CN Patent CN105769857A, 2016.
[37]
Yinglu, Z. Acne-removing composition and preparation method thereof. CN Patent CN107684530A, 2018.
[38]
Xiaohui, C.; Jian, C.; Tianhui, X.; Lijin, Q.; Lijing, B. Antibacterial and anti-inflammation pyridone composition and cosmetic comprising same. CN Patent CN110693754A, CN110693754B, 2020.
[39]
Magaña Castro, J.A.; Vázquez Cervantes, L.; Peña, S.P. Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne. US Patent US10792258B2, 2020.
[40]
Rudolph, T.; Mueller, T. Use of cyclohexanol derivatives as antimicrobial active ingredients. RU Patent RU2014129611A, 2016.
[41]
Masatoshi, H.; Matsushita, R.; Miyama, K. Biofilm formation inhibitor. JP Patent JP2016210751A, 2016.
[42]
Young Mog, K.; Hwan, O. J.; Jung Won, K. Composition for preventing or treating Acne containing oligo-chitosan as an effective component. KR Patent KR101838404B1, 2018.
[43]
Soung, M. G.; Choi, W. S.; Jun, S.J.; Jeong, Y. P. Cosmetic composition for treating acne. KR Patent KR101689878B1, 2016.
[44]
Jeung, P.H. Composition for improving skin acne comprising quercetin and vitamin D. KR Patent KR20180135169A, 2018.
[45]
Dabney, P. Methods for treating acne vulgaris. US Patent US10016456B2, US2016015744A1, 2016.
[46]
Bommagani, M.; Bhowmick, S. B.; Kane, P.; Dubey, V. Nanoparticulate composition. US Patent US2018036243A1, WO2016135754A1, 2018.
[47]
Ping, L.; Morten, O.; Hasling Frandsen, C.; Hanne, M. Non-aqueous topical compositions comprising a halogenated salicylanilide. MX Patent MX2018011249A, 2019.
[48]
Cheng, H.; Rui, H.; Kejian, Z. Polypeptide having anti-bacterial and anti-inflammatory activity and application thereof. CN Patent CN106589088A, CN106589088B 2017.
[49]
Caires, C. Systems and methods for treating and/or preventing acne. US Patent US11116714B2, 2020.
[50]
Jeffry, B. S.; Maxwell, S. Use of anti-bacterial agent for the treatment of epithelial-related conditions. JP Patent JP2017190345A, WO2011060330A1, 2017.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy